Ameriprise
RGLS

Ameriprise’s Regulus Therapeutics RGLS Stock Holding History

Ameriprise’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,325
Closed -$1.1M – 3836
2016
Q1 		$1.1M Buy
1,325
+126
+11% +$100K ﹤0.01% 2802
2015
Q4 		$1.25M Sell
1,199
-973
-45% -$975K ﹤0.01% 2846
2015
Q3 		$1.7M Sell
2,172
-260
-11% -$267K ﹤0.01% 2706
2015
Q2 		$3.2M Sell
2,432
-4,155
-63% -$6.7M ﹤0.01% 2443
2015
Q1 		$13.4M Sell
6,587
-400
-6% -$869K 0.01% 1317
2014
Q4 		$13.4M Buy
6,987
+6,985
+349,250% +$12.4M 0.01% 1260
2014
Q3 		$1K Buy
2
+1
+100% +$846 ﹤0.01% 5570
2014
Q2 		$1K Buy
+1
New +$857 ﹤0.01% 5368
2013
Q4 		– Sell
-5
Closed -$6K – 5383
2013
Q3 		$6K Hold
5
– – ﹤0.01% 5165
2013
Q2 		$5K Buy
+5
New +$4.75K ﹤0.01% 5137

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's RGLS Position: Q2 2016 in Review

Ameriprise sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 1,325 shares — an estimated $1.1M sold.

Ameriprise first reported a position in RGLS in Q2 2013 and held it in 10 quarters. The position peaked at $13.4M in Q4 2014. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Ameriprise reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Ameriprise sold 1,325 Regulus Therapeutics shares in Q2 2016, an estimated $1.1M.
  • Ameriprise first reported a position in Regulus Therapeutics in Q2 2013 and held it in 10 quarters.
  • Ameriprise's Regulus Therapeutics position peaked at $13.4M in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Ameriprise's 13F filing for Q2 2016, filed 8 Aug 2016.